Advocacy intelligence hub — real-time data for patient organizations
Princess Maxima Center for Pediatric Oncology — PHASE1, PHASE2
Children's Oncology Group — PHASE1
GUSTAVO SALGUERO — NA
Cairo University — NA
Johns Hopkins University — PHASE2, PHASE3
University of Alabama at Birmingham — NA
National Cancer Institute (NCI) — NA
National Cancer Institute (NCI) — PHASE2
University of Washington — PHASE2
Novartis Pharmaceuticals — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance13
Arranon
Novartis
Rylaze
Jazz
BLINCYTO
Amgen
Marqibo
Acrotech Biopharma LLC
Oncaspar; Asparlas
Servier Pharmaceuticals LLC
Aucatzyl
Autolus Incorporated, US subsidiary of Autolus Limited
Clolar
Genzyme Corporation
Nelarabine
Novartis
Methotrexate Sodium
Pfizer
Xatmep
Azurity
Erwinase
Jazz Pharmaceuticals, Inc.
Besponsa
Pfizer
CLOFARABINE
Sanofi
Aucatzyl
(obecabtagene autoleucel)Orphan drugAutolus Incorporated, US subsidiary of Autolus Limited
12.1 Mechanism of Action AUCATZYL is a CD19-directed genetically modified autologous T cell immunotherapy consisting of the patient's own T cells expr...
Blincyto
(blinatumomab)Orphan drugAmgen, Inc.
12.1 Mechanism of Action Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-linea...
Rylaze
(asparaginase erwinia chrysanthemi (recombinant)-rywn)Orphan drugJazz Pharmaceuticals Ireland Limited
Asparagine-specific Enzyme [EPC]
12.1 Mechanism of Action Asparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagin...
Marqibo
(vinCRIStine sulfate LIPOSOME injection)Orphan drugAcrotech Biopharma LLC
Erwinase
(Erwinia L-asparaginase)Orphan drugJazz Pharmaceuticals, Inc.
Arranon
(nelarabine)Orphan drugNovartis Pharmaceuticals Corp.
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Nelarabine is a prodrug of the deoxyguanosine analogue 9-β- D -arabinofuranosylguanine (ara-G), a nucleoside metabolic inhibi...
Clolar
(clofarabine)Orphan drugGenzyme Corporation
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Clofarabine is sequentially metabolized intracellularly to the 5’-monophosphate metabolite by deoxycytidine kinase and mono- ...
Oncaspar; Asparlas
(Pegaspargase)Orphan drugServier Pharmaceuticals LLC
Asparagine-specific Enzyme [EPC]
12.1 Mechanism of Action L-asparaginase is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The ...
[Recent advances in individualized treatment for pediatric high-risk B-cell acute lymphoblastic leukemia].
B-cell acute lymphoblastic leukemia (B-ALL) is the most common hematologic malignancy in children. High-risk B-ALL, due to factors such as poor early treatment response and adverse genetic features, i...
Parent Quality of Life at Two Years Following Their Child's Completion of Acute Lymphoblastic Leukemia Treatment.
Parents of children treated for acute lymphoblastic leukemia (ALL) often experience significant caregiver burden and disruption to their well-being. While parent quality of life (QoL) during treatment...
Cytomegalovirus Reactivation During Therapy for Pediatric Acute Lymphoblastic Leukemia.
Cytomegalovirus (CMV) reactivation is a recognized complication after hematopoietic stem cell transplantation, but its relevance during conventional chemotherapy for pediatric acute lymphoblastic leuk...
Investigating autophagy and miRNAs as therapeutic targets in leukemia.
Leukemia, characterized by the uncontrolled proliferation of abnormal white blood cells, encompasses several subtypes, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chron...
Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia.
Ph-like ALL, a high-risk subgroup of B-cell ALL, is associated with a poor prognosis. The genetic diversity observed across different ethnicities underscores the importance of population-specific stud...
The combination therapy with venetoclax in therapeutic strategy of acute lymphoblastic leukemia.
Acute lymphoblastic leukemia (ALL) is characterized by the malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood, and extramedullary sites. Leukemic cells c...
Hagop Kantarjian, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Lewis B Silverman
Children's Hospital of Alabama
📍 Birmingham, Alabama
Srdan Verstovsek, MD, M.D., PhD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Irene Sarosiek, MD
Texas Tech University Health Sciences Center
Farhad Ravandi-Kashani, M.D
SWOG Cancer Research Network
📍 HOUSTON, TX
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V